These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 24002123)

  • 1. The cancer‑testis antigen NXF2 is activated by the hypomethylating agent decitabine in acute leukemia cells in vitro and in vivo.
    Zhou J; Li Y; Yao Y; Wang L; Gao L; Gao X; Luo X; Li J; Jiang M; Zhou M; Wang L; Yu L
    Mol Med Rep; 2013 Nov; 8(5):1549-55. PubMed ID: 24002123
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment of chronic lymphocytic leukemia with a hypomethylating agent induces expression of NXF2, an immunogenic cancer testis antigen.
    Dubovsky JA; McNeel DG; Powers JJ; Gordon J; Sotomayor EM; Pinilla-Ibarz JA
    Clin Cancer Res; 2009 May; 15(10):3406-15. PubMed ID: 19401350
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Expression of PD-L1, PD-L2, PD-1 and CTLA4 in myelodysplastic syndromes is enhanced by treatment with hypomethylating agents.
    Yang H; Bueso-Ramos C; DiNardo C; Estecio MR; Davanlou M; Geng QR; Fang Z; Nguyen M; Pierce S; Wei Y; Parmar S; Cortes J; Kantarjian H; Garcia-Manero G
    Leukemia; 2014 Jun; 28(6):1280-8. PubMed ID: 24270737
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cancer-testis antigen expression and its epigenetic modulation in acute myeloid leukemia.
    Atanackovic D; Luetkens T; Kloth B; Fuchs G; Cao Y; Hildebrandt Y; Meyer S; Bartels K; Reinhard H; Lajmi N; Hegewisch-Becker S; Schilling G; Platzbecker U; Kobbe G; Schroeder T; Bokemeyer C; Kröger N
    Am J Hematol; 2011 Nov; 86(11):918-22. PubMed ID: 21898529
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Gene expression profiling of myelodysplastic CD34+ hematopoietic stem cells treated in vitro with decitabine.
    Giachelia M; D'Alò F; Fabiani E; Saulnier N; Di Ruscio A; Guidi F; Hohaus S; Voso MT; Leone G
    Leuk Res; 2011 Apr; 35(4):465-71. PubMed ID: 20869114
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Decitabine has a biphasic effect on natural killer cell viability, phenotype, and function under proliferative conditions.
    Kopp LM; Ray A; Denman CJ; Senyukov VS; Somanchi SS; Zhu S; Lee DA
    Mol Immunol; 2013 Jul; 54(3-4):296-301. PubMed ID: 23328088
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Decitabine induces very early in vivo DNA methylation changes in blasts from patients with acute myeloid leukemia.
    Claus R; Pfeifer D; Almstedt M; Zucknick M; Hackanson B; Plass C; Lübbert M
    Leuk Res; 2013 Feb; 37(2):190-6. PubMed ID: 23158571
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The euphoria of hypomethylating agents in MDS and AML: is it justified?
    Sekeres MA
    Best Pract Res Clin Haematol; 2013 Sep; 26(3):275-8. PubMed ID: 24309530
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vivo effects of decitabine in myelodysplasia and acute myeloid leukemia: review of cytogenetic and molecular studies.
    Hackanson B; Robbel C; Wijermans P; Lübbert M
    Ann Hematol; 2005 Dec; 84 Suppl 1():32-8. PubMed ID: 16292549
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Differential TERT promoter methylation and response to 5-aza-2'-deoxycytidine in acute myeloid leukemia cell lines: TERT expression, telomerase activity, telomere length, and cell death.
    Pettigrew KA; Armstrong RN; Colyer HA; Zhang SD; Rea IM; Jones RE; Baird DM; Mills KI
    Genes Chromosomes Cancer; 2012 Aug; 51(8):768-80. PubMed ID: 22517724
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The DNA demethylating agent 5-aza-2'-deoxycytidine induces expression of NY-ESO-1 and other cancer/testis antigens in myeloid leukemia cells.
    Almstedt M; Blagitko-Dorfs N; Duque-Afonso J; Karbach J; Pfeifer D; Jäger E; Lübbert M
    Leuk Res; 2010 Jul; 34(7):899-905. PubMed ID: 20381863
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 5-Aza-2'-deoxycytidine induces p21WAF expression by demethylation of p73 leading to p53-independent apoptosis in myeloid leukemia.
    Schmelz K; Wagner M; Dörken B; Tamm I
    Int J Cancer; 2005 May; 114(5):683-95. PubMed ID: 15609309
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hypomethylation and up-regulation of PD-1 in T cells by azacytidine in MDS/AML patients: A rationale for combined targeting of PD-1 and DNA methylation.
    Ørskov AD; Treppendahl MB; Skovbo A; Holm MS; Friis LS; Hokland M; Grønbæk K
    Oncotarget; 2015 Apr; 6(11):9612-26. PubMed ID: 25823822
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting epigenetic pathways in acute myeloid leukemia and myelodysplastic syndrome: a systematic review of hypomethylating agents trials.
    Yun S; Vincelette ND; Abraham I; Robertson KD; Fernandez-Zapico ME; Patnaik MM
    Clin Epigenetics; 2016; 8():68. PubMed ID: 27307795
    [TBL] [Abstract][Full Text] [Related]  

  • 15. p53-inducible ribonucleotide reductase (p53R2/RRM2B) is a DNA hypomethylation-independent decitabine gene target that correlates with clinical response in myelodysplastic syndrome/acute myelogenous leukemia.
    Link PA; Baer MR; James SR; Jones DA; Karpf AR
    Cancer Res; 2008 Nov; 68(22):9358-66. PubMed ID: 19010910
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Genome-wide methylation profiling in decitabine-treated patients with acute myeloid leukemia.
    Yan P; Frankhouser D; Murphy M; Tam HH; Rodriguez B; Curfman J; Trimarchi M; Geyer S; Wu YZ; Whitman SP; Metzeler K; Walker A; Klisovic R; Jacob S; Grever MR; Byrd JC; Bloomfield CD; Garzon R; Blum W; Caligiuri MA; Bundschuh R; Marcucci G
    Blood; 2012 Sep; 120(12):2466-74. PubMed ID: 22786882
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Analysis of genome-wide methylation and gene expression induced by 5-aza-2'-deoxycytidine identifies BCL2L10 as a frequent methylation target in acute myeloid leukemia.
    Fabiani E; Leone G; Giachelia M; D'alo' F; Greco M; Criscuolo M; Guidi F; Rutella S; Hohaus S; Voso MT
    Leuk Lymphoma; 2010 Dec; 51(12):2275-84. PubMed ID: 21077739
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Characterization of DNA demethylation effects induced by 5-Aza-2'-deoxycytidine in patients with myelodysplastic syndrome.
    Mund C; Hackanson B; Stresemann C; Lübbert M; Lyko F
    Cancer Res; 2005 Aug; 65(16):7086-90. PubMed ID: 16103056
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Methylation silencing of the Apaf-1 gene in acute leukemia.
    Furukawa Y; Sutheesophon K; Wada T; Nishimura M; Saito Y; Ishii H; Furukawa Y
    Mol Cancer Res; 2005 Jun; 3(6):325-34. PubMed ID: 15972851
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Epigenetics in clinical practice: the examples of azacitidine and decitabine in myelodysplasia and acute myeloid leukemia.
    Estey EH
    Leukemia; 2013 Sep; 27(9):1803-12. PubMed ID: 23757301
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.